Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Preeclampsia is a major cause of illness and deaths among mothers and their babies globally. Preeclampsia is a kind of high blood pressure that occur in some women after the 20th week of pregnancy or after giving birth. This severe pregnancy disorder occurs in up to 5% of all pregnancies. It is one of the leading hypertensive disorders of pregnancy across the developed and emerging countries. It may lead to preterm birth and other complications, such as failure of organs, seizure or eclampsia, and death if it is not diagnosed at an early stage.
The Global Preeclampsia Diagnostics Market is estimated to be valued at US$ 1,270.1 billion in 2021 and is expected to exhibit a CAGR of 11.8% during the forecast period (2021-2028).
Figure 1.Global Preeclampsia Diagnostics Market Share (%) in Terms of Value, By Product Type 2021
Increasing prevalence of preeclampsia is expected to drive the market growth during the forecast period.
Increasing perinatal and maternal morbidity & mortality rate is set to surge the need for the early diagnosis of preeclampsia worldwide among pregnant women, which is expected to drive the global preeclampsia diagnostics market growth over the forecast period. For instance, according to the Preeclampsia Foundation, over 10 million women globally develop preeclampsia every year, and approximately 2.5 million preterm birth are caused by preeclampsia annually. The disorder is affecting both neonates and mothers in the developed and developing nations.
Preeclampsia Diagnostics Market Report Coverage
||Market Size in 2021:
||US$ 1,270.1 Mn
|Historical Data for:
||2017 to 2020
||2021 to 2028
|Forecast Period 2021 to 2028 CAGR:
||2028 Value Projection:
||US$ $ 2,780.4 Mn
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC Countries, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
- By Test Type: Blood Tests, Urine Analysis, Others
- By Product Type: Instruments, Consumables
- By End User: Hospital, Specialty Clinics, Diagnostic Centers, Others
Diabetomics, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, PerkinElmer Inc., Siemens Healthineers AG, DRG INSTRUMENTS GMBH, Metabolomic Diagnostics Ltd., Sera Prognostics, MOMM Diagnostics, Miraculins Inc.
- Increasing prevalence of preeclampsia
- Increasing launches of new product
- Increasing research and development for new tests to detect biomarkers indicating preeclampsia
|Restraints & Challenges:
- Lack of awareness about the preeclampsia disease
Figure 2.Global Preeclampsia Diagnostics Market Share (%), By Test Type, 2021
Increasing product launches for preeclampsia expected to drive the market growth during the forecast period
Increasing launches of new product by key players is expected to boost the market growth during the forecast period. For instance, in February 2019, Diabetomics, is a global commercial stage medical diagnostics company announced the launch of Lumella, a rapid point-of-care test for Preeclampsia in Hyderabad, India.
Global Preeclampsia Diagnostics Market – Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus (COVID-19) has resulted in more than 212 million infected individuals worldwide as of August 24 2021.
COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drugs from one place to another.
Furthermore, players operating in the global preeclampsia diagnostics market are facing major challenges on various fronts due to the COVID-19 pandemic. The major challenges include supply of raw materials required for manufacturing drug formulations due to irregularities in transportation. Moreover, distributors are experiencing irregular demand for products from the retailers due to an increase in the number of patients suffering from COVID-19 and other life threatening disorders.
Global Preeclampsia Diagnostics Market: Restraint
The major factors that hinder the growth of the global preeclampsia diagnostics market include lack of awareness about the preeclampsia disease. According to a survey conducted by Progenity, Inc. in May 2021, for cause of maternal death reveals pregnant women lack awareness about preeclampsia. Nearly 30% of pregnant women in the United States experience signs and symptoms of possible preeclampsia. Approximately 5-8% of all pregnancies are complicated by preeclampsia.
Major players operating in the global preeclampsia diagnostics market are Diabetomics, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, PerkinElmer Inc., Siemens Healthineers AG, DRG INSTRUMENTS GMBH, Metabolomic Diagnostics Ltd., Sera Prognostics, MOMM Diagnostics, Miraculins Inc.